MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

562.3M

Vuru Grade

31.00/100

Current Price

$10.93
+0.28 (+2.63%)

Stability Price

$0.30
Overvalued by 97.22%

Company Metrics

  • 13.83 P/E
  • 14.18 P/S
  • 2.21 P/B
  • -2.186 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 636,783.00 Avg. Vol.
  • 51.45M Shares
  • 562.3M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial ...
MarketWatch - Jul 15, 2014
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) , a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2014 before the U.S.
Momenta Pharmaceuticals Sees Large Increase in Short Interest (MNTA)
WKRB News - Jul 18, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02.
Bearish runners – IAMGOLD Corp (USA) (IAG), Momenta Pharmaceuticals, Inc ...
Techsonian (press release) - Jul 25, 2014
Momenta Pharmaceuticals, Inc.(NASDAQ:MNTA) is a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel ...
Momenta Pharmaceuticals Sees Large Growth in Short Interest (MNTA)
Ticker Report - Jul 17, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, beating the analysts' consensus estimate of ($0.55) by $0.02.
Investors Are Watching - Microsoft Corporation (NASDAQ:MSFT), GoPro Inc ...
Markets Insider - Jul 25, 2014
On July 15, 2014, Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Vertex Pharmaceuticals Incorporated (NYSE: VRX) entered into the fourth amendment to the sublease agreement (the “Amendment”) for Momenta's corporate headquarters at 675 West ...
Trader's Buzzers–Spherix (NASDAQ:SPEX), Rock Creek Pharmaceuticals ...
Techsonian (press release) - Jul 8, 2014
Momenta Pharmaceuticals, Inc.(MNTA), a biotechnology company, is involved in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs.
Drugs Generic: Actavis plc (NYSE:ACT), Horizon Pharma Inc (NASDAQ:HZNP ...
Crazy Joys - Jun 30, 2014
On June 17, Momenta Pharmaceuticals Inc (NASDAQ:MNTA) has earned an average recommendation of “Buy” from the eight analysts that are covering the stock, StockRatingsNetwork.
Stocks in the News–Meritor (NYSE:MTOR), Vantage Drilling Company (VTG ...
Techsonian (press release) - Jul 25, 2014
Momenta Pharmaceuticals, Inc.(MNTA) is a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs.
Morrison & Foerster - The California Powerhouse
Lawfuel - 8 hours ago
Last year, MoFo also scored an impressive victory on behalf of Sandoz and Momenta Pharmaceuticals Inc., Sandoz's collaborative partner.
Tufts study: Orphan drug approvals up, but high costs pose challenges
Boston Globe - Jul 10, 2014
Orphan drugs - developed to treat rare diseases - are being approved at a faster rate, but in many cases, US patients will be paying more out-of-pocket costs, according to a Tufts University study.